Results 161 to 170 of about 4,771 (191)
Some of the next articles are maybe not open access.
Belinostat approved for use in treating rare lymphoma
American Journal of Health-System Pharmacy, 2014FDA on July 3 announced it approved the marketing of belinostat, or Beleodaq, for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Richard Pazdur, head of FDA’s Office of Hematology and Oncology Products, said the drug is the third one that the agency has approved ...
openaire +1 more source
Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework
Biomedical ChromatographyABSTRACT Belinostat (PXD101), a hydroxamate‐class histone deacetylase inhibitor (HDACi), was approved by the US FDA for patients with relapsed or refractory peripheral T‐cell lymphoma (PTCL). This review covers belinostat's pharmacological characteristics (including its mode of action), pharmacokinetics, toxicity, drug interactions ...
Sanket Chaudhari +4 more
openaire +2 more sources
Molecular Cancer Therapeutics
Abstract The phase III study of romidepsin plus CHOP for peripheral T-cell lymphoma (PTCL) yielded negative results in the overall analysis and showed that outcomes were only improved in the T follicular helper (TFH) subgroup of PTCL, with no benefit in non–TFH PTCL. Belinostat, another histone deacetylase (HDAC) inhibitor, is now the
Jacob C. Pantazis, Adam C. Palmer
openaire +2 more sources
Abstract The phase III study of romidepsin plus CHOP for peripheral T-cell lymphoma (PTCL) yielded negative results in the overall analysis and showed that outcomes were only improved in the T follicular helper (TFH) subgroup of PTCL, with no benefit in non–TFH PTCL. Belinostat, another histone deacetylase (HDAC) inhibitor, is now the
Jacob C. Pantazis, Adam C. Palmer
openaire +2 more sources
Spectrum and TopoTarget in US$350 M Deal for Belinostat
PharmaDeals Review, 2010Spectrum Pharmaceutical is paying US$30 M upfront for TopoTarget’s Phase III lymphoma drug, belinostat, a histone deacetylase (HDAC) inhibitor in development for the treatment of peripheral T cell lymphoma (PTCL). The drug has been granted orphan drug and fast track designation by the FDA.
openaire +1 more source

